register

News & Trends - Pharmaceuticals

National Cabinet revises COVID-19 vaccine strategy impacting use of Pfizer and AstraZeneca vaccines

Health Industry Hub | April 23, 2021 |
[Total: 1    Average: 4/5]

Pharma News: The National Cabinet met yesterday to discuss Australia’s COVID-19 response and changes to the Australian COVID-19 Vaccine Strategy.

Australia’s COVID-19 vaccine roll out continues to expand. To date, 1,785,698 doses of COVID-19 vaccines have been administered in Australia. The number of administration sites has expanded, with 4,500 general practices as well as general practice respiratory centres and Aboriginal health services now administering COVID-19 vaccinations.

“We are now at 7 per 100, which puts us ahead of the European Union, ahead of countries like Belgium and France and Italy and of course, countries like New Zealand and Canada at the same time of their vaccination rollout,” said Prime Minister Scott Morrison.

National Cabinet agreed to recalibrate the delivery model for the COVID-19 Vaccination Rollout Strategy, taking into account the Australian Technical Advisory Group on Immunisation (ATAGI) medical advice on the use of AstraZeneca vaccines.

Limiting access to the Pfizer vaccine to:

  • People aged under 50 years eligible in phases 1a and 1b
  • Residential Aged Care Facility (RACF) residents
  • Disability care residents with complex needs who require in-reach vaccination services
  • People in remote and very remote communities

Better utilisation of the available stock of AstraZeneca doses: by bringing forward access to the AstraZeneca COVID-19 vaccine for phase 2a eligible people aged 50–69 years commencing with General Practice Respiratory Clinics (GPRCs) and state and territory COVID-19 vaccination sites from 3 May 2021 and General Practice (GP) clinics from 17 May 2021.

Increasing access to the Pfizer vaccine: by immediately opening state and territory-operated sites to eligible people, including under 50 year old aged care and disability care workers; and establishing a Pfizer mass vaccination plan, which includes state and territory mass vaccination sites and large GP and GPRC sites.

Maintaining the lead role for GPs in administering the AstraZeneca vaccine: as demand exists and supply permits, allocating more doses to GPs.

Supplementing the role of GPs: with states and territories continuing to operate AstraZeneca COVID-19 vaccination sites and services where required to supplement the primary care network and immediately opening these sites to people aged 50 years and over and eligible in phases 1a and 1b.

Making better use of some vaccination sites: by permitting state and territory-operated vaccination sites to operate Pfizer and AstraZeneca services from one site, provided the site is large enough to allow for complete clinical separation of the two services.

States and territories can choose to incorporate community pharmacies: (which were originally due to commence from Phase 2a) into their roll-out plans in rural and remote areas where there are no or limited other points of presence.

National Cabinet also agreed the revised COVID-19 vaccine national roll-out strategy which, in light of the age-based preferential Pfizer vaccine recommendation, adjusts the age cut-off for Aboriginal and Torres Strait Islander people eligible in phase 1b to ‘50 years and over’ (down from 55 years and over) and expands eligibility in phase 2b to 16 and 17 year olds (now that Pfizer is the preferred vaccine for this age group and is approved for use in 16 and 17 year olds).

The Commonwealth will further contribute 50% of the additional costs incurred by states and territories to set up additional COVID-19 clinics after 21 April 2020, where necessary to support the recalibrated delivery model.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Digital & Innovation

Healthcare Technology Digital Innovations - Genomics industry making headlines at HealthData21

Genomics industry making headlines at HealthData21

Health Industry Hub | May 13, 2021 |

Australia’s new genomics industry alliance Industry Genomics Network Alliance (InGeNA) will bring together representatives from the key sectors of diagnostics, […]

More


News & Trends - Medical Technology

MedTech News - B. Braun launches renal care centre in NSW and QLD

B. Braun launches renal care centres in NSW and QLD

Health Industry Hub | May 13, 2021 |

MedTech News: B. Braun, one of the world’s leading providers of medical devices, dialysis products and renal care services has […]

More


News & Trends - Pharmaceuticals

Pharma News - BMS immunotherapy combo approved in aggressive thoracic cancer

BMS immunotherapy combo approved in aggressive thoracic cancer

Health Industry Hub | May 13, 2021 |

Pharma News: Bristol-Myers Squibb (BMS) welcomed the Therapeutics Goods Administration (TGA) registration of its immunotherapy combination drugs for the first-line […]

More


News & Trends - Pharmaceuticals

Pharma News - GSK bridges the skills gap between academia and pharma industry

GSK bridges the skills gap between academia and pharma industry

Health Industry Hub | May 13, 2021 |

Pharma News: Six PhD graduates have recently traded in their lab coats for laptops after landing a place in a […]

More